Multiple Myeloma Clinical Trial

Beta-glucan and Fatigue in HSCT Survivors

Summary

This is a single-center, randomized, double-blind, placebo-controlled study exploring the effects of a yeast-derived β-glucan on clinically significant fatigue among survivors of autologous HCT due to multiple myeloma. The primary aim is to evaluate the effect of β-glucan supplementation on changes in fatigue symptoms, as assessed by the Brief Fatigue Inventory (BFI) global fatigue score, by testing the differences in changes in scores from baseline to the mid-point (mean of weeks 1-4) and to the end of the intervention (mean of weeks 5-8).

View Full Description

Full Description

Fatigue is one of the most prevalent and distressing complications among hematopoietic cell transplantation HCT survivors, affecting up to 80% of patients. Fatigue has a significant negative impact on the physical, functional, social, and emotional domains of quality of life. Therefore, special attention should be directed toward therapeutic interventions in reducing persistent fatigue, which in turn improves quality of life of this patient population. Research is needed to determine if yeast-derived β-glucan regulates inflammatory disruption and fatigue in patient populations. This study will investigate the efficacy of β-glucan supplementation on fatigue symptoms in autologous HCT survivors due to multiple myeloma. The primary aim is to evaluate the effect of β-glucan supplementation on changes in fatigue symptoms, as assessed by the BFI global fatigue score, by testing the differences in changes in scores from baseline to the mid-point (mean of weeks 1-4) and to the end of the intervention (mean of weeks 5-8). Secondary objectives will be to evaluate tolerability, adverse events, inflammatory cytokines, quality of life, sleep disturbance, pain, anxiety, and depression.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Be ≥ 18 years of age.
Be an autologous HSCT survivor with clinically significant fatigue (determined post-consent). Clinically significant fatigue is defined as BFI global score greater than 3.0.
Have a medical history of the first autologous HSCT due to multiple myeloma approximately 30 days before starting the study intervention.
Be willing and able to provide written informed consent.
Be willing and able to comply with all the study-related procedures, including attending study visits for the blood draws, intake of the study supplement, and completing study questionnaires.

Exclusion Criteria:

Have an active infection.
Have disease relapse.
Have absolute neutrophil count less than 500.
Have anemia and thrombocytopenia requiring transfusions.
Have an untreated medical condition that could clinically explain fatigue in this population (i.e., untreated hypothyroidism).
Have begun to take antidepressants less than 30 days from enrollment.
Demonstrate an inability to comply with the study and/or follow-up procedures.
Use probiotic supplements. The subjects can participate if they are willing to stop taking probiotics. A one-month withdrawal from probiotics is required

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

3

Study ID:

NCT05524688

Recruitment Status:

Terminated

Sponsor:

University of Florida

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Shands at University of Florida
Gainesville Florida, 32608, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

3

Study ID:

NCT05524688

Recruitment Status:

Terminated

Sponsor:


University of Florida

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.